The FDA has made public dozens of warning letters sent to drug companies accused of misleading or deceptive advertising.
The disclosures come after the agency said Sept. 9 it would be sending thousands of warning letters and 100 cease-and-desist letters to drug companies over deceptive advertising.
A day later, President Donald Trump signed an executive order directing HHS and the FDA to require drug companies to include full safety warnings in advertisements. The warning letters outline alleged violations and can lead to regulatory action if companies choose to not comply.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
